Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) Chairman Brian Jamieson Address At Annual General Meeting.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the first group of patients who received the lowest dose of Revascor(TM), the proprietary "off-the-shelf" adult stem cell product for heart failure, continued to show sustained improvement in heart muscle function at six months.
Benitec Limited (ASX:BLT)(PINK:BNIKF) Chairman Mr Peter Francis Address to Annual General Meeting.
Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) today announced successful results from the first 18 patients receiving a bone marrow transplant using umbilical cord blood expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).
Sirtex Medical (ASX:SRX)(PINK:SXMDF) has delivered record revenues and profit. Highlights include; total product revenue for the year ended 30 June 2009 was A$65.6 million, up 72 per cent on the previous year. Net profit after tax of A$18.2 million was up 1,406 per cent on the last year. SIR-Spheres microspheres dose sales were up 42 per cent to 3,658 doses.
Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) has secured intellectual property rights that underpin its second HIV therapeutic program. This program is a multi-project effort centered at City of Hope to investigate HIV-based vector delivery of anti-HIV RNA (pHIV7-shI-TAR-CCR5RZ) to CD4 T cells as a clinical modality.
